TROY Protein, Human, Recombinant (Fc Tag) Product Information
> 85 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
Testing in progress
A DNA sequence encoding the human TNFRSF19 (Q9NS68-2) (Met1-Leu170) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
Predicted N Terminal
The recombinant human TNFRSF19/Fc is a disulfide-linked homodimer. The reduced monomer comprises 382 amino acids and has a predicted molecular mass of 42.5 kDa. The apparent molecular mass of the protein is approximately 52-57 kDa in SDS-PAGE under reducing conditions.
Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us
for any concerns or special requirements.Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -70℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
TROY Protein, Human, Recombinant (Fc Tag) in SDS-PAGE
TROY Protein, Human, Recombinant (Fc Tag) Alternative Names
TAJ Protein, Human;TAJ-alpha Protein, Human;TNFRSF19 Protein, Human;TRADE Protein, Human;TROY Protein, Human
TROY Background Information
Tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), also known as TAJ-alpha or TROY, is a member of the TNF-receptor superfamily. TNFRSF19/TROY expression is detected in the pulmonary epithelium and the ductal epithelium of the prostate and parotid glands. TNFRSF19/TROY expression is detected in some adenocarcinoma cell lines that arise from this tissue. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. TNFRSF19/TROY is capable of inducing apoptosis by a caspase-independent mechanism, and it is thought to play an essential role in embryonic development. TNFRSF19/TROY was negatively regulated by adipogenic transcription factor CCAAT/enhancer-binding proteins (C/EBP). TNFRSF19 signals activation of the Jnk pathway and induces cell death. Overexpression of TNFRSF19 also signals NFB activation, comparable and similar to that by p75NGFR. TNFRSF19/TROY is capable of activating key signaling pathways of the TNF receptor family, and its predominant expression patterns suggest that it plays a role in the growth and regulation of epithelial tissues.
tumor necrosis factor receptor superfamily, member 19
Hu S, et al. (1999) Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics. 62(1): 103-7.Qiu W, et al. (2010) Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem. 285(19): 14438-49.Hisaoka T, et al. (2006) Characterization of TROY/TNFRSF19/TAJ-expressing cells in the adult mouse forebrain. Brain Res. 1110(1): 81-94.